

The following table shows the financial results for Merck & Co., Inc. and subsidiaries for the quarter ended March 31, 2007, compared with the corresponding period of the prior year.

Merck & Co., Inc.  
Consolidated Results  
(In Millions Except Earnings per Common Share)  
Quarter Ended March 31  
(Unaudited)

	<u>2007</u>	<u>2006</u>	<u>% Change</u>
Sales	\$5,769.4	\$5,409.8	7%
Costs, Expenses and Other			
Materials and production <sup>(1)</sup>	1,525.8	1,342.7	14
Marketing and administrative	1,802.0	1,715.0	5
Research and development <sup>(2)</sup>	1,030.0	942.0	9
Restructuring costs <sup>(3)</sup>	65.8	43.7	51
Equity income from affiliates	(652.6)	(503.4)	30
Other (income) expense, net <sup>(4)</sup>	(256.0)	(100.6)	*
Income Before Taxes	2,254.4	1,970.4	14
Taxes on Income	550.1	450.4	
Net Income	\$1,704.3	\$1,520.0	12
Average Shares Outstanding			
Assuming Dilution	2,180.0	2,190.5	
Earnings per Common Share			
Assuming Dilution	\$0.78	\$0.69	13

\* > 100%

(1) Includes restructuring costs of \$118.1 million in 2007 and \$205.0 million in 2006 primarily related to accelerated depreciation and asset impairment costs associated with Merck's global restructuring program announced in November 2005.

(2) Includes restructuring costs of \$2.2 million in 2007 and \$55.4 million in 2006 primarily related to accelerated depreciation costs associated with the global restructuring program.

(3) Restructuring costs in 2007 and 2006 represent separation and other related costs associated with the global restructuring program.

(4) The increase primarily reflects the favorable impact of gains on sales of assets and product divestitures.